Recent:
Lee
Cui
Huang. Submit updates/corrections .
May 1
|
Ursodeoxycholic acid for COVID-19: real-time meta analysis of 13 studies | |
Statistically significant lower risk is seen for recovery and cases. 7 studies from 7 independent teams in 3 countries show statistically significant improvements. Meta analysis using the most serious outcome reported shows 17% [5.. | ||
Apr 4
|
et al., Pharmacology Research & Perspectives, doi:10.1002/prp2.1194 | Ursodeoxycholic acid may protect from severe acute respiratory syndrome coronavirus 2 Omicron variant by reducing angiotensin‐converting enzyme 2 |
Syrian hamster study showing ursodeoxycholic acid (UDCA) may protect against SARS-CoV-2 omicron variant transmission and infection. Hamsters treated prophylactically with oral UDCA had significantly less weight loss compared to untreated .. | ||
Mar 20
|
et al., Journal of Clinical Hepatology, doi:10.12449/JCH240309 | Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B |
48% faster recovery (p=0.01) and 83% fewer cases (p=0.001). Retrospective 215 patients with chronic hepatitis B in China, showing lower risk of COVID-19 infection, milder symptoms, and faster recovery with ursodeoxycholic acid (UDCA) treatment. | ||
Feb 13
|
et al., Acta Pharmaceutica Sinica B, doi:10.1016/j.apsb.2024.02.011 | Bile acids and coronavirus disease 2019 |
Review of the relationship between bile acids and COVID-19. Authors discuss emerging basic and clinical evidence linking bile acids to COVID-19 infection and potential mechanisms. Functionally, studies indicate that certain bile acids lik.. | ||
Jan 19
|
et al., Journal of Medical Virology, doi:10.1002/jmv.29418 | Exploring the impact of ursodeoxycholic acid therapy on COVID‐19 in a real‐word setting |
19% lower ICU admission (p=1) and 40% lower hospitalization (p=0.17). Retrospective cohort study of 10,147 chronic liver disease patients in France, with 1,322 exposed to ursodeoxycholic acid (UDCA), showing lower risk of hospitalization for COVID-19 with UDCA exposure, without statistical significance (adj.. | ||
Dec 13
2023 |
et al., medRxiv, doi:10.1101/2023.12.11.23299191 | Ursodeoxycholic acid and severe COVID-19 outcomes in people with liver disease: a cohort study using the OpenSAFELY platform |
24% lower mortality (p=0.13), 19% lower hospitalization (p=0.02), and 21% lower combined mortality/hospitalization (p=0.005). OpenSAFELY retrospective 11,320 primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) patients showing lower risk of COVID-19 hospitalization or death with ursodeoxycholic acid (UDCA) treatment. | ||
Dec 9
2023 |
et al., Biochemical Pharmacology, doi:10.1016/j.bcp.2023.115983 | Bile acids and bile acid activated receptors in the treatment of Covid-19 |
Review of the potential role of bile acids and bile acid activated receptors in modulating SARS-CoV-2 infectivity and inflammation in COVID-19. Authors discuss mechanisms by which bile acids like ursodeoxycholic acid (UDCA), chenodeoxycho.. | ||
Nov 28
2023 |
et al., Blood, doi:10.1182/blood-2023-182862 | Effect of Ursodeoxycholic Acid for Sars-Cov-2 Prevention in Hematological Malignancies: An Observational Real-World Study |
12% fewer cases (p=0.03). Retrospective 393 hospitalized patients with hematologic disorders in China, showing lower risk of COVID-19 with UDCA use. | ||
Nov 16
2023 |
et al., Microbiology and Infectious Diseases The American Medical Journal, doi:10.33590/microbiolinfectdisamj/10304488 | A Retrospective Study in Patients With Varying Prescription Coverage With Ursodeoxycholic Acid and Association With Incidence of COVID-19 Diagnosis in Primary Care |
13% fewer cases (p=0.03). Retrospective 8,964 primary care patients prescribed ursodeoxycholic acid (UDCA) in the UK. Higher categorized UDCA adherence (≥80%) was associated with lower COVID-19 incidence (OR 0.86), whereas adherence as a continuous variable was no.. | ||
Sep 21
2023 |
et al., Liver International, doi:10.1111/liv.15736 | Ursodeoxycholic acid does not affect the clinical outcome of |
7% higher mortality (p=0.77). PSM retrospective 629 hospitalized COVID-19 patients showing no significant difference in survival between 108 patients taking UDCA prior to infection compared to 521 matched controls not taking the drug. The lack of observed benefit in t.. | ||
Aug 22
2023 |
et al., Journal of Internal Medicine, doi:10.1111/joim.13711 | UDCA treatment against COVID‐19: Do we have enough clinical evidence for drug repurposing? |
7% higher mortality (p=0.67), 4% lower ICU admission (p=0.96), 6% higher hospitalization (p=0.66), and 3% fewer cases (p=0.77). Retrospective cohort study of 9,617 patients with liver disease in Italy, divided into UDCA users and non-users. UDCA exposure was not associated with reduced SARS-CoV-2 infection or improved COVID-19 outcomes including death, hospitaliza.. | ||
Aug 14
2023 |
et al., Viruses, doi:10.3390/v15081738 | Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients |
no change in mortality (p=0.24). Retrospective 3,847 COVID-19 patients hospitalized in Italy, including 57 treated with UDCA. UDCA treatment was not associated with reduced mortality, however treatment was associated with a lower rate of CPAP use. It's not clear how the .. | ||
Jul 27
2023 |
et al., Journal of Internal Medicine, doi:10.1111/joim.13704 | Ursodeoxycholic acid for coronavirus disease 2019 prevention |
17% fewer symptomatic cases (p=0.81) and no change in cases (p=1). Retrospective 94 outpatients attending a university hospital gastroenterology clinic in Japan showing no significant difference in SARS-CoV-2 infection rates between ursodeoxycholic acid (UDCA)-treated patients and control groups without .. | ||
Jun 29
2023 |
et al., Liver International, doi:10.1111/liv.15660 | Ursodeoxycholic acid administration did not reduce susceptibility to |
2% more cases (p=0.88). Retrospective 280 Chinese families with children previously seen in a liver clinic assessing whether ursodeoxycholic acid (UDCA) reduced SARS-CoV-2 infection risk. Among infected families, the study found no significant difference in conf.. | ||
May 4
2023 |
et al., medRxiv, doi:10.1101/2023.05.02.23289410 | UDCA May Promote COVID-19 Recovery: A Cohort Study with AI-Aided Analysis |
38% improved recovery (p=0.05). Retrospective 115 COVID-19 patients hospitalized during an Omicron outbreak in China, of which 65 received ursodeoxycholic acid (UDCA) treatment and 50 received standard care. It found that UDCA was associated with faster body temperature.. | ||
May 3
2023 |
et al., Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2023.1178590 | Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease |
80% lower severe cases (p=0.22), 80% fewer moderate/severe cases (p<0.0001), and 11% fewer cases (p=0.05). Retrospective propensity score matched cohort study of 225 chronic liver disease patients on UDCA therapy matched to 225 controls without UDCA in China. UDCA use was associated with lower COVID-19 infection rate (85% vs 94%), lower maximu.. | ||
Apr 5
2023 |
et al., Journal of Internal Medicine, doi:10.1111/joim.13630 | Ursodeoxycholic acid is associated with a reduction in SARS‐CoV‐2 infection and reduced severity of COVID‐19 in patients with cirrhosis |
46% fewer cases (p<0.0001). Retrospective 3,214 veterans with cirrhosis comparing 1,607 participants taking ursodeoxycholic acid (UDCA) to 1,607 propensity score matched controls not taking UDCA. UDCA use was associated with significantly lower odds of SARS-CoV-2 in.. | ||
Dec 5
2022 |
et al., Nature, doi:10.1038/s41586-022-05594-0 | FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 |
94% lower mortality (p=0.13), 75% lower ICU admission (p=0.21), and 40% lower hospitalization (p=0.03). Retrospective study from two registries of 1,096 COVID-19 patients with chronic liver disease, including 31 treated with ursodeoxycholic acid (UDCA). Propensity score matching was used to compare outcomes between UDCA-treated and untreate.. |
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.